Spine gurus K2M, Inc. have announced the promotion of Gianluca Iasci, formerly K2M’s Senior Vice President for International Sales, to the position of Executive Vice President, Global Sales. Iasci will continue to report to Eric Major, President and CEO of K2M. Iasci will be responsible for the company’s global distribution and expansion efforts in both the United States and international markets.
Gianluca Iasci Promoted at K2M

“I am confident that Gianluca’s international view of the world will provide strong leadership to our global mission of delivering leading technologies to surgeons and patients. His hands-on customer centric management style and emphasis on performance accountability will help us continue to achieve rapid growth, as he brings the same degree of strategy and execution discipline to his management of the U.S. market, ” said Major in the May 8, 2013 news release.
Prior to joining K2M, Mr. Iasci served as Senior Vice President of International at AGA Medical Corporation and served for 12 years with Johnson & Johnson in various European sales and marketing positions. He also was the managing director of Italy while at Guidant Corporation, now Boston Scientific Corporation, and spent four years at St. Jude Medical, Inc. where he was stationed in Hong Kong and gained experience in the Asia Pacific Market.
Major added, “Since joining K2M, Gianluca has been instrumental in establishing and expanding direct sales operations in the UK, Germany, Switzerland, Austria, Italy and Scandinavia, as well as our business in Spain, Australia, New Zealand, Japan and the Middle East. The global alignment of our sales organization under Gianluca in this new, unified role is an important milestone in K2M’s strategic plan to become the worldwide leader in complex spine and minimally invasive technologies.”
A K2M representative told OTW, “Having worked in Europe, the Middle East, Africa, and Asia for over 20 years leading medical device business to exceed customer expectations, Gianluca’s prior experience has more than prepared him for further expanding K2M’s global sales operations.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.